NCI Definition: The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent. The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO) 
There are 2 clinical trials for fibrillary astrocytoma, of which 2 are open and 0 are completed or closed. Of the trials that contain fibrillary astrocytoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Apx005m, bevacizumab, and cetuximab are the most common interventions in fibrillary astrocytoma clinical trials.
Significant Genes in Fibrillary Astrocytoma
H3F3A is an inclusion eligibility criterion in 1 clinical trial for fibrillary astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and fibrillary astrocytoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.